Serum levels of adipokines in gestational diabetes: a systematic review

Bellos, Ioannis; Fitrou, Georgia; Pergialiotis, Vasilios; Περρέα, Δέσποινα; Daskalakis, G.

doi:10.1007/s40618-018-0973-2

Cited by 35 publications

(29 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chen et al found that FGF21 levels increased progressively with dysglycemia and concluded that FGF21 could predict the development of diabetes in a large Chinese prospective study [25]. To our knowledge, ours is the first meta-analysis of the relationship between circulating FGF21 levels and GDM although previously, systematic reviews have bene published by Yuan et al and Bellos et al [9,26]. In both reviews of Yuan et al and Bellos et al, statistical analysis was not performed to draw an exact conclusion between circulating FGF21 levels and GDM.…”

Section: Discussionmentioning

confidence: 77%

Circulating levels of fibroblast growth factor 21 in gestational diabetes mellitus: a meta-analysis

et al. 2021

View full text Add to dashboard Cite

In recent times, the role of fibroblast growth factor 21 (FGF21) in patients with gestational diabetes mellitus (GDM) has been increasingly investigated. However, to our knowledge, no systematic analysis has been conducted yet to evaluate the relationship between FGF21 levels and GDM. Confirmed studies related to circulating FGF21 levels and GDM were searched from the databases of PubMed, ISI Web of Science, MEDLINE and EMBASE. Data were reported as standard mean difference (SMD) and associated 95% confidence intervals (CIs). Analysis were performed with Review Manager 5.2 and Stata version 11.0. A total of 392 cases and 435 controls in nine articles were included in this meta-analysis. The circulating FGF21 levels in pregnant women with GDM was higher than that in controls (random effects MD [95% CI] = 0.46, [0.07-0.86], p = 0.02). The result of multivariate meta-regression showed that sample size and point of sample collection contributed to heterogeneity (p = 0.033 and p = 0.047, respectively). Additionally, the results showed that there was no publication bias in this meta-analysis (Z = 1.36, p = 0.175; t = 1.24, p = 0.256, respectively). To conclude, this meta-analysis provides evidence that circulating FGF21 levels are higher in GDM subjects than controls, and it is important to clarify the relationship between circulating FGF21 levels and pregnant women with GDM in accurate prediction of GDM.

show abstract

Section: Discussionmentioning

confidence: 77%

Circulating levels of fibroblast growth factor 21 in gestational diabetes mellitus: a meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Prospective studies of FABP4 and GDM are limited, 8 25 with the majority of previous studies being cross-sectional or retrospective. 32 In a study among 1150 Chinese women (GDM cases n=135), FABP4 at ~6 GWs was positively associated with subsequent risk of developing GDM. 8 However, in a study among 123 Australian women who were mostly (84%) Caucasian, and had a prior GDM pregnancy, there were no differences in FABP4 levels at approximately 14 GWs or 28 GWs between women with and without recurrent GDM.…”

Section: Discussionmentioning

confidence: 99%

Adipokines in early and mid-pregnancy and subsequent risk of gestational diabetes: a longitudinal study in a multiracial cohort

Francis

Hinkle

et al. 2020

BMJ Open Diab Res Care

View full text Add to dashboard Cite

IntroductionSeveral adipokines are implicated in the pathophysiology of gestational diabetes mellitus (GDM), however, longitudinal data in early pregnancy on many adipokines are lacking. We prospectively investigated the association of a panel of adipokines in early and mid-pregnancy with GDM risk.Research design and methodsWithin the National Institute of Child Health and Human Development (NICHD) Fetal Growth Studies-Singletons cohort (n=2802), a panel of 10 adipokines (plasma fatty acid binding protein-4 (FABP4), chemerin, interleukin-6 (IL-6), leptin, soluble leptin receptor (sOB-R), adiponectin, omentin-1, vaspin, and retinol binding protein-4) were measured at gestational weeks (GWs) 10–14, 15–26, 23–31, and 33–39 among 107 GDM cases (ascertained on average at GW 27) and 214 non-GDM controls. Conditional logistic regression was used to estimate ORs of each adipokine and GDM, controlling for known GDM risk factors including pre-pregnancy body mass index.ResultsThroughout pregnancy changes in chemerin, sOB-R, adiponectin, and high-molecular-weight adiponectin (HMW-adiponectin) concentrations from 10–14 to 15–26 GWs were significantly different among GDM cases compared with non-GDM controls. In early and mid-pregnancy, FABP4, chemerin, IL-6 and leptin were positively associated with increased GDM risk. For instance, at 10–14 GWs, the OR comparing the highest versus lowest quartile (ORQ4–Q1) of FABP4 was 3.79 (95% CI 1.63 to 8.85). In contrast, in both early and mid-pregnancy adiponectin (eg, ORQ4–Q1 0.14 (0.05, 0.34) during 10–14 GWs) and sOB-R (ORQ4–Q1 0.23 (0.11, 0.50) during 10–14 GWs) were inversely related to GDM risk. At 10–14 GWs a model that included conventional GDM risk factors and FABP4, chemerin, sOB-R, and HMW-adiponectin improved the estimated prediction (area under the curve) from 0.71 (95% CI 0.66 to 0.77) to 0.77 (95% CI 0.72 to 0.82).ConclusionsA panel of understudied adipokines including FABP4, chemerin, and sOB-R may be implicated in the pathogenesis of GDM with significant associations detected approximately 10–18 weeks before typical GDM screening.

show abstract

“…Among the 806 articles retrieved, 31 were eligible; 14 were FABP4 studies [8,[17][18][19][26][27][28][29][30][31][32][33][34][35][36], seven were nesfatin-1 studies [10,12,20,[37][38][39][40], seven were OC studies [14,21,[41][42][43][44][45], and three articles covered both FABP4 and nesfatin-1 [11,46,47]. The 31 studies involved 4590 participants; 2059 were GDM patients and 2531 were healthy pregnant women [8, 10-12, 14, 17-21, 26-47] (Fig.…”

Section: Study Characteristicsmentioning

confidence: 99%

Circulating FABP4, nesfatin-1, and osteocalcin concentrations in women with gestational diabetes mellitus: a meta-analysis

Sun

Zhang

et al. 2020

Lipids Health Dis

View full text Add to dashboard Cite

Objective: Recent studies have investigated the circulating adipocyte fatty acid binding protein (FABP4), nesfatin-1, and osteocalcin (OC) concentrations in women diagnosed with gestational diabetes mellitus (GDM), but the findings prove to be conflicting. The objective of this research was to systematically assess the relationship of circulating levels of above adipokines with GDM. Methods: Pubmed, Embase, Web of Science, Cochrane library, OVID, and Scopus were performed to locate articles published up to January 31, 2020. Pooled standard mean differences (SMDs) with 95% confidence intervals (CIs), and 95% predictive intervals (PIs) were calculated by random-effects models to compare levels of adipokines between GDM cases and control groups. Cumulative and single-arm meta-analyses were also performed. Results: Thirty-one studies comprising 4590 participants were included. No significant differences were found between GDM women and healthy controls in circulating nesfatin-1 levels (4.56 vs. 5.02 ng/mL; SMD = − 0.11, 95% CI-0.61-0.38, 95% PI-1.63-1.41). Nevertheless, circulating FABP4 and OC levels observed in GDM women outnumbered normal controls (FABP4, 23.68 vs. 16.04 ng/mL; SMD = 2.99, 95% CI 2.28-3.69, 95% PI 0.28-5.71; OC, 52.34 vs. 51.04 ng/mL; SMD = 0.68, 95% CI 0.31-1.05, 95% PI-0.48-1.84). The cumulative meta-analysis showed that the SMDs of circulating FABP4 and OC levels had stabilized between the two groups. Conclusions: Elevated circulating FABP4 and OC levels were observed in GDM women, but nesfatin-1 levels did not change, the PI of OC crossed the no-effect threshold. The results suggested that FABP4 is more suitable as a biomarker of GDM compared to OC in a future study, which is useful in identifying pregnant women who are likely to develop GDM and providing prompt management strategies.

show abstract

Serum levels of adipokines in gestational diabetes: a systematic review

Cited by 35 publications

References 117 publications

Circulating levels of fibroblast growth factor 21 in gestational diabetes mellitus: a meta-analysis

Circulating levels of fibroblast growth factor 21 in gestational diabetes mellitus: a meta-analysis

Adipokines in early and mid-pregnancy and subsequent risk of gestational diabetes: a longitudinal study in a multiracial cohort

Circulating FABP4, nesfatin-1, and osteocalcin concentrations in women with gestational diabetes mellitus: a meta-analysis

Contact Info

Product

Resources

About